Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
HBAR’s Double Bottom Meets Deutsche Bank Integration

HBAR’s Double Bottom Meets Deutsche Bank Integration

DailyCoinDailyCoin2026/10/12 20:06

The new HBAR integration revolves around Taurus, a Swiss digital asset infrastructure provider founded in 2018 in Geneva. This big player provides enterprise-grade technology platforms that banks and other regulated financial institutions use to custody, issue coins, tokenize securities, trade, stake & manage miscellaneous digital assets.

$64 Billion German Banking Giant Adopts HBAR

The Swiss infra provider has unleashed the full Hedera Hashgraph (HBAR) tech stack for their clients, including Deutsche Bank, one of Europe’s largest banks. The German giant is now able to stake Hedera’s native HBAR coin natively via Taurus’ platform, also issuing their own tokenized shares of Real World Assets (RWAs) & private equity.

Crypto custody also plays an important role in this HBAR adoption story. Deutsche Bank is able to monetize their own securities on-chain, while staking HBAR at the same time. The $64 billion behemoth joins the likes of Jane Street, Lloyd Bank, Standard Bank & Shinhan Bank, all of which have been actively exploring the HBAR Network for RWAs.

HBAR Hits Double Bottom Upon Council Shift

Hedera’s operating body, the Governing Council, includes other large enterprises (Google, IBM, Deutsche Telekom, Accenture, FedEx & more), which supports institutional trust, but the above are the clearest major banking-sector players successfully adopting the HBAR stack in their every-day business deeds.

A few weeks back, Hitachi stepped away from the council, leaving 33 members on board. This didn’t have any particular affect on the price of the altcoin. Presently, HBAR’s price is defending a double-bottom establishment between $0.08 to $0.09. This type of setups tend to arrive before a price trend switch occurs.

This could potentially take HBAR back to the quarterly highs of $0.22, crypto analyst Gopal said. 

The long-term target would be $0.35, basing this double-bottom on an earlier outcome from 2025. HBAR arrived at $0.30 in August, 2025, hitting the same bottom at roughly $0.09 before the $0.22 resistance was conquered in a 30-day rally. Now, bulls keep HBAR above the $0.092 support with not much back-up from whales.

The one-day HBAR price charts pin-point selling sentiment across big-time players, as HBAR’s Chaikin Money Flow (CMF) dwelled around -0.07. Similar slightly-negative figures were printed out on smaller time-frames, according to TradingView. The near-term projection points to $0.11 as a crucial level to restore, aligning with the Red-Label Bollinger Band (BOLL).

News Image 0
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11